Skip to content

ILC Research Trend From Then To Now

Scope

This digest is an entry-level map of how the ILC field, especially lung and airway ILC research, moved from discovery to disease mechanism. It is not a bibliometric history of every ILC paper. Instead, it follows selected landmark and source-reviewed papers to explain what researchers learned at each stage, why those discoveries changed the field, and where our own work (Ya-Jen Chang, Christina Li-Ping Thio, and Jheng-Syuan Shao) fits within that broader trajectory.

The central trend is simple: ILC research moved from asking whether innate lymphoid cells exist and matter, to asking which ILC state acts in which tissue niche, during which disease phase, through which regulatory pathway.

One-Sentence Orientation

For beginners, the safest mental model is: ILCs are tissue-positioned innate lymphocytes that can rapidly produce cytokines and repair mediators without antigen-specific receptors, but their function depends strongly on subset identity, activation state, tissue compartment, disease trigger, and timing.

Conceptual Timeline

Period What the field learned Lung and disease meaning Representative anchors
Pre-2011 discovery era Innate lymphoid biology began to expand beyond classical NK cells and lymphoid tissue inducer-like cells. The field was moving toward the idea that non-T, non-B lymphoid cells could organize barrier immunity, inflammation, and tissue homeostasis. Lung relevance was still emerging. ILCs were not yet widely used as a disease-mechanism framework for airway physiology. Broad reviews: ILC 10 years on, The biology of innate lymphoid cells
2011 lung functional anchoring Lung ILCs became functionally important, not just phenotypic curiosities. Influenza studies showed that ILCs could shape airway physiology and tissue repair after viral injury. This period created the first strong lung-disease logic: ILC activation can be pathogenic in one context and reparative in another. Influenza-induced AHR via innate lymphoid/natural-helper cells, post-influenza lung homeostasis via amphiregulin-associated ILC repair
2013-2016 classification and tissue mapping ILC1, ILC2, and ILC3 frameworks became the language for organizing transcription factors, cytokine programs, and tissue distributions. Human lung characterization and review literature helped stabilize the field vocabulary. Lung studies could now distinguish IL-5/IL-13 ILC2 biology from IL-17A/IL-22 ILC3 biology, rather than treating all innate lymphoid activity as one phenomenon. human lung ILC subsets, ILC diversity and plasticity review, lung ILC3 IL-22 in pneumococcal infection, IGF1 neonatal pulmonary ILC3 niche
2016-2021 plasticity and regulation The field learned that ILC subset labels are useful but incomplete. ILCs can acquire memory-like behavior, shift cytokine programs, respond to metabolic cues, and change under inflammatory pressure. Disease interpretation became more nuanced: the relevant question became not only "ILC2 or ILC3?" but "which ILC state, induced by which trigger?" allergen-experienced memory-like ILC2s, ILC2 PD-L1 checkpoint control of Th2 polarization, COPD-associated ILC2 plasticity, IL-17-producing ST2+ ILC2s, human ILC2-to-IL-17 plasticity in nasal inflammation, reciprocal ILC3 transcription factor networks
2022-2026 disease-state, niche, and boundary-aware era Recent work increasingly connects ILC programs to disease endotypes, local stromal and epithelial niches, neuroimmune circuits, metabolism, adaptive-immunity interfaces, and lineage-boundary questions. Lung ILC research now asks how ILC2 and ILC3 states participate in allergic asthma, viral injury, neutrophilic asthma, steroid resistance, smoking-associated asthma, tissue repair, and extrapulmonary mechanisms that may or may not translate to the lung. BATF protective ILC2 repair during respiratory virus infection, smoke-associated memory-like ILC3s, glucocorticoid-insensitive ILC3 neutrophil chemoattractants, HIF-1alpha/glycolysis control of ILC2s, mTORC1-neuroimmune ILC2 regulation, ILC2-Gata3high Treg feedback, fibroblast SCF/KIT-ILC3 neutrophilic asthma, human severe-asthma sputum ILC2/ILC3 boundary states, PDGF-D divergent ILC3 responses, RORgammat-positive dendritic-cell lineage boundary

Knowledge Evolution Flowchart

flowchart TB
    accTitle: ILC Knowledge Evolution
    accDescr: Vertical timeline showing how ILC research evolved from discovery into lung functional biology, subset taxonomy, plasticity, niche mechanisms, and boundary-aware disease biology.

    A["Pre-2011<br/>ILCs emerge beyond NK/LTi framing"] --> B["2011<br/>Lung functional anchoring"]
    B --> C["2013-2016<br/>Subset taxonomy and tissue mapping"]
    C --> D["2016-2021<br/>Plasticity, memory, and regulation"]
    D --> E["2022-2026<br/>Disease states, niches, and boundaries"]
    E --> F["Current field<br/>context-resolved mechanisms"]

    R1["Our 2011 role<br/>viral AHR"] -.-> B
    R2["Our 2018 role<br/>butyrate brake"] -.-> D
    R3["Our 2025 role<br/>SCF/KIT-ILC3"] -.-> E

    classDef era fill:#e8f3ff,stroke:#3b6ea8,stroke-width:2px,color:#17324d
    classDef current fill:#eef7ed,stroke:#4d8a50,stroke-width:2px,color:#173d1d
    classDef our_work fill:#fff4de,stroke:#b47a1f,stroke-width:2px,color:#4a3108

    class A,B,C,D,E era
    class F current
    class R1,R2,R3 our_work

How Understanding Changed Over Time

1. From cell discovery to lung physiology

Early ILC research established that innate lymphoid cells are not simply minor lymphocyte contaminants. They are tissue-integrated immune cells capable of rapid cytokine and repair-mediator production. The lung became a major test bed when influenza studies showed two apparently opposite functions: innate lymphoid/natural-helper-cell pathways can drive airway hyperreactivity through IL-33/IL-13, while lung ILCs can also support epithelial integrity and lung function after influenza injury through amphiregulin-associated repair.

This is the first major lesson for beginners: "ILC activation" is not intrinsically good or bad. The same broad cell family can contribute to disease physiology or tissue recovery depending on timing, mediator, and injury context.

2. From one innate lymphoid idea to subset-resolved biology

The next major advance was the ILC1, ILC2, and ILC3 framework. This allowed lung immunologists to separate type 2 cytokine biology from IL-17A/IL-22 biology and from ILC1-like inflammatory programs. Human lung subset characterization provided a direct pulmonary anchor, while ILC3 studies in pneumococcal infection, neonatal lung development, and ARDS-like inflammation made clear that ILC3s could not be treated as only gut-resident cells.

Subset language is useful but never sufficient. Every claim still needs tissue, species, model, and assay context.

3. From fixed subsets to plastic and memory-like states

By the late 2010s, the field increasingly treated ILCs as stateful cells. Allergen-experienced ILC2s can acquire memory-like properties. COPD-associated triggers can push ILC2s toward ILC1-like inflammatory programs. IL-17-producing ST2+ ILC2-like cells and human nasal ILC2-to-IL-17 plasticity complicate strict ILC2-versus-ILC3 boundaries. ILC3 identity is also shaped by reciprocal transcription factor networks.

The practical implication is that disease-associated ILCs should be described as states when possible, not just as subsets. A phrase like "ILC2s are increased" is much less informative than "IL-33-responsive, IL-5/IL-13-producing lung ILC2s are increased in this mouse allergic airway model" or "human nasal ILC2s can acquire IL-17-producing features under IL-1beta/IL-23/TGF-beta conditions."

4. From presence to regulation

The field then moved from detecting ILCs to regulating ILC function. ILC2 studies highlight cysteinyl leukotriene signaling, CXCL16-dependent accumulation, autophagy, HIF-1alpha/glycolysis, mTORC1-linked neuroimmune crosstalk, butyrate/HDAC-linked suppression, SCF/c-Kit regulation, IL-1beta restraint in early-life rhinovirus models, and gammaherpesvirus-driven macrophage reprogramming. ILC3 studies highlight IGF1 developmental niches, IL-17A in ARDS-like inflammation, acetylcholine in protease-driven pathology, smoke-associated memory-like ILC3s, glucocorticoid-insensitive neutrophil chemoattractant production, fibroblast-derived SCF/KIT regulation, and gut/mucosal regulatory comparators such as RANKL/RANK, circadian timing, FFAR2, VIP circuits, trained defense states, and HB-EGF tissue protection.

This stage also sharpened the standard for interpretation: each regulatory node should be attached to the exact ILC subset or state, the disease model, and the evidence type.

5. From general ILC biology to pulmonary disease endotypes

The most recent literature is increasingly endotype-aware. Asthma is no longer treated as a single ILC2-dominated type 2 disease. Current lung ILC interpretation increasingly separates eosinophilic/type 2 asthma, viral airway hyperreactivity, steroid-resistant asthma, neutrophilic asthma, smoking-associated asthma, ARDS-like acute injury, respiratory infection, and repair.

This matters because therapeutic imagination changes when the mechanism changes. Targeting an IL-33/IL-13 ILC2 axis is conceptually different from targeting a fibroblast SCF/KIT-ILC3-IL-17A-neutrophil axis, and both are different from supporting BATF-associated repair ILC2 states during acute viral injury.

Role Of Our Research In This Trajectory

Our research axis is not a side note; it sits at several important inflection points in lung ILC biology.

  • Ya-Jen Chang first-author, 2011: the influenza-induced AHR study helped establish that innate lymphoid/natural-helper-cell pathways can mediate airway physiology independently of adaptive TH2 immunity. In this timeline, it belongs to the lung functional anchoring phase.
  • Christina Li-Ping Thio first-author, 2018: the butyrate study helped move the field from ILC2 presence and activation toward functional regulation, showing that butyrate can suppress ILC2 cytokine output and ILC2-dependent AHR in reported systems. In this timeline, it belongs to the regulation and plasticity phase.
  • Christina Li-Ping Thio first-author, 2019: the TLR9-dependent interferon source serves here as a source-reviewed anchor for a negative regulatory pathway in which TLR9/type I IFN/NK-cell IFN-gamma/STAT1 signaling suppresses ILC2-driven AHR.
  • Jheng-Syuan Shao first-author, 2025: the pulmonary fibroblast-derived SCF study anchors a modern stromal-niche mechanism for ILC3-driven neutrophilic asthma-like inflammation. In this timeline, it belongs to the disease-endotype and tissue-niche mechanism phase.

Beginner Reading Path

  1. Start with the two 2011 influenza papers to learn why lung ILCs matter physiologically.
  2. Read the 2015-2016 review and human lung characterization pages to understand ILC subset language.
  3. Move to ILC2 plasticity, memory-like ILC2s, and ILC3 identity papers to understand why subset labels are not enough.
  4. Use Lung ILC Core Evidence Synthesis for a cross-subset map, and Lung ILC Disease Roles Companion when you want the same biology rearranged by pathology.
  5. Read ILC2 and ILC3 for cell-level mechanisms and interpretation boundaries.

Claim-Level Confidence Boundaries

  • High confidence: the broad trajectory from discovery to subset classification to state- and niche-specific disease mechanisms is well supported across multiple primary studies and mature reviews.
  • High confidence: the 2011 lung influenza papers support the concept that lung ILCs can affect airway physiology and repair, but those claims should remain tied to the specific viral-injury settings and historical nomenclature.
  • Medium-high confidence: ILC2 and ILC3 regulatory nodes such as butyrate/HDAC, HIF-1alpha/glycolysis, mTORC1, BATF, smoke-associated memory-like ILC3s, glucocorticoid-insensitive ILC3 programs, SCF/KIT, human sputum ILC2/ILC3 boundary states, and species-aware PDGF-D responses are coherent mechanism axes, but their generality differs by model, tissue, receptor context, and source type.
  • Medium confidence: lineage-boundary and adaptive-interface sources are important for interpretation because RORgammat-positive, antigen-presenting, or cytokine-producing cells should not automatically be assigned to ILC3 biology without marker, lineage, tissue, and functional evidence.
  • Medium confidence: translational claims about human asthma endotypes are strongest when human samples are paired with mechanistic mouse or ex vivo perturbation evidence; human association alone should not be overstated as causality.
  • Low confidence: any claim that a single ILC subset, mediator, or pathway explains all asthma, all viral lung disease, or all pulmonary inflammation should be rejected unless future evidence is much stronger.

Future Expansion Directions

  • Revisit this page when a newly reviewed source changes the timing or interpretation of an ILC discovery phase.
  • Add a new row if human lung, BAL, sputum, bronchial biopsy, or spatial single-cell studies directly connect ILC states to clinical outcomes in asthma, COPD, ARDS, pneumonia, fibrosis, or lung cancer.
  • Revisit the 2019 TLR9-dependent interferon axis if new human airway or lung-tissue studies test whether this inhibitory ILC2 pathway is conserved in asthma endotypes.

Representative Source Spine